JD Health International 将来の成長

Future 基準チェック /36

JD Health International利益と収益がそれぞれ年間14.6%と10.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に7.7% 14.1%なると予測されています。

主要情報

14.6%

収益成長率

14.1%

EPS成長率

Consumer Retailing 収益成長	29.4%
収益成長率	10.5%
将来の株主資本利益率	7.7%
アナリストカバレッジ	Good
最終更新日	28 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

SHSC:6618 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	72,321	3,902	7,946	7,122	17
12/31/2025	64,844	3,550	6,757	5,556	19
12/31/2024	57,729	3,109	5,220	4,557	19
6/30/2024	54,764	2,618	6,436	6,467	N/A
3/31/2024	54,147	2,380	5,490	5,536	N/A
12/31/2023	53,530	2,142	4,544	4,605	N/A
9/30/2023	53,576	1,930	3,135	4,311	N/A
6/30/2023	53,621	1,718	1,726	4,017	N/A
3/31/2023	50,179	1,049	2,679	4,961	N/A
12/31/2022	46,736	380	3,632	5,905	N/A
9/30/2022	42,003	-7	3,440	4,829	N/A
6/30/2022	37,270	-395	3,249	3,753	N/A
3/31/2022	33,976	-734	3,085	3,592	N/A
12/31/2021	30,682	-1,074	2,921	3,431	N/A
9/30/2021	27,463	-6,702	4,068	4,352	N/A
6/30/2021	24,243	-12,331	5,216	5,274	N/A
3/31/2021	21,813	-14,783	4,439	4,487	N/A
12/31/2020	19,383	-17,234	3,662	3,699	N/A
9/30/2020	17,007	-11,901	1,980	2,004	N/A
6/30/2020	14,631	-6,567	298	309	N/A
3/31/2020	12,737	-3,769	351	359	N/A
12/31/2019	10,842	-972	404	409	N/A
12/31/2018	8,169	215	185	187	N/A
12/31/2017	5,553	179	N/A	36	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 6618の予測収益成長率 (年間14.6% ) は貯蓄率 ( 2.3% ) を上回っています。

収益対市場: 6618の収益 ( 14.6% ) はHong Kong市場 ( 11.5% ) よりも速いペースで成長すると予測されています。

高成長収益: 6618の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: 6618の収益 ( 10.5% ) Hong Kong市場 ( 7.8% ) よりも速いペースで成長すると予測されています。

高い収益成長: 6618の収益 ( 10.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 6618の自己資本利益率は、3年後には低くなると予測されています ( 7.7 %)。

JD Health International 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Recent updates

Investor sentiment deteriorates as stock falls 17%

Insufficient new directors

Now 22% overvalued after recent price rise

Investor sentiment improves as stock rises 15%

First half 2024 earnings released: EPS: CN¥0.65 (vs CN¥0.50 in 1H 2023)

JD Health International Inc. Announces Appointment of Professor George Lau as Independent Non-Executive Director

JD Health International Inc. to Report First Half, 2024 Results on Aug 15, 2024

Now 23% undervalued after recent price drop

Now 21% undervalued

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc., Annual General Meeting, Jun 21, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment deteriorates as stock falls 15%

Full year 2023 earnings released: EPS: CN¥0.69 (vs CN¥0.12 in FY 2022)

JD Health International Inc. to Report Q4, 2023 Results on Mar 20, 2024

Investor sentiment deteriorates as stock falls 17%

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 18%

First half 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.072 in 1H 2022)

JD Health International Inc. to Report First Half, 2023 Results on Aug 16, 2023

Now 23% undervalued

Independent Non-Executive Director recently sold HK$108k worth of stock

JD Health International Inc. Announces Chief Financial Officer Changes

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.35 loss in FY 2021)

CEO & Executive Director recently sold HK$5.1m worth of stock

Independent Non-Executive Director recently sold HK$55k worth of stock

First half 2022 earnings released: EPS: CN¥0.07 (vs CN¥0.15 loss in 1H 2021)

JD Health International Inc. to Report First Half, 2022 Results on Aug 23, 2022

Chairman recently sold HK$195m worth of stock

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

JD Health International Inc. Announces Board Changes

JD Health International Inc. (SEHK:6618) announces an Equity Buyback for HKD 3,000 million worth of its shares.

Full year 2021 earnings released: CN¥0.35 loss per share (vs CN¥7.80 loss in FY 2020)

Independent Non-Executive Director recently sold HK$61k worth of stock

Non-Executive Director Pang Zhang has left the company

First half 2021 earnings released: CN¥0.15 loss per share (vs CN¥2.49 loss in 1H 2020)

Full year 2020 earnings released: CN¥7.80 loss per share (vs CN¥0.45 loss in FY 2019)

Non-Executive Director has left the company

Independent Non-Executive Director has left the company

Full year 2020 earnings released: CN¥7.80 loss per share

JD Health International Inc. to Report Fiscal Year 2020 Results on Mar 29, 2021

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘